ABSTRACT
Copper storage disease occurs in multiple dog breeds and is one of the most common causes of chronic hepatitis in this species. The disease is caused by hereditary defects in copper metabolism in conjunction with high dietary copper levels. The progressive copper accumulation leads to hepatitis, cirrhosis, and eventually death if left untreated. Copper chelators are critical in modulating the effects of this disease. It is therefore of significant practicality to understand the pharmacokinetic (PK) parameters of chelating agents, particularly since they are oftentimes quite expensive. A liquid chromatography-tandem mass spectrometric (LC/MS/MS) method was developed to measure plasma levels of one of the most common chelators, d-penicillamine. The compound was discovered to exist in two forms, monomeric and dimeric, and various chemical derivatizations were tried to force the compound into one form or the other. Eventually, the simplest approach was individual determination of penicillamine and its dimer, with summation of the two quantities. This enabled determination of canine PK parameters for penicillamine based on comparison of oral and intravenous administration of the drug, including time to maximum drug level (Tmax), concentration at maximum (Cmax), clearance (Cls) and volume of distribution (Vdss). The drug was found to exist predominantly in the dimeric form in plasma, which is incapable of chelating copper owing to lack of free sulfhydryl groups and must therefore provide a storage form of the drug in equilibrium with its monomeric form in vivo. Mechanisms are discussed for the electrospray-induced fragmentation of penicillamine as well as of its dimer.
Subject(s)
Chelating Agents/pharmacokinetics , Chromatography, Liquid , Drug Monitoring , Penicillamine/pharmacokinetics , Spectrometry, Mass, Electrospray Ionization , Tandem Mass Spectrometry , Administration, Intravenous , Administration, Oral , Animals , Chelating Agents/administration & dosage , Dogs , Female , Male , Models, Biological , Penicillamine/administration & dosage , Penicillamine/blood , Reproducibility of ResultsABSTRACT
In the synthesis of technetium-99m (99mTc) labeled target-specific ligands, the presence of a large excess of unlabeled ligands over 99mTc in the injectate hinders target accumulation of 99mTc-labeled ligands by competing for target molecules. To circumvent the problem, we recently developed a concept of the metal coordination-mediated multivalency, and proved the concept with a 99mTc-labeled trivalent compound [99mTc(CO)3(CN-RGD)3]+. In this study, D-penicillamine (Pen) was selected as a chelating molecule and a cyclic RGDfK peptide was conjugated to Pen via a hexanoic linkage (Pen-Ahx-c(RGDfK)). 99mTc complexation reaction, and the stability, integrin αvß3 binding affinity, and biodistribution of the 99mTc-labeled probe were investigated to evaluate the applicability of the concept to bivalent probes. 99mTc-[Pen-Ahx-c(RGDfK)]2 was obtained over 95% radiochemical yields under low Pen-Ahx-c(RGDfK) concentration (50 µM). 99mTc-[Pen-Ahx-c(RGDfK)]2 showed approximately 10-times higher integrin αvß3 binding affinity than the monovalent compounds, Pen-Ahx-c(RGDfK) and c(RGDyV). In biodistribution studies, the tumor accumulation of 99mTc-[Pen-Ahx-c(RGDfK)]2 was decreased to 77% and 43% of HPLC-purified (Pen-Ahx-c(RGDfK)-free) 99mTc-[Pen-Ahx-c(RGDfK)]2 by the presence of 5 nmol of unlabeled Pen-Ahx-c(RGDfK) and Re-[Pen-Ahx-c(RGDfK)]2, respectively. 99mTc-[Pen-Ahx-c(RGDfK)]2 provided tumor image without removing unlabeled ligand, while a 99mTc-labeled monovalent probe prepared from a monovalent ligand could not. These findings indicate the availability of the design concept to prepare 99mTc-labeled bivalent probes with a variety of 99mTc core and other metallic radionuclides of clinical relevance.
Subject(s)
Chelating Agents/chemistry , Neoplasms/diagnostic imaging , Organotechnetium Compounds/chemistry , Penicillamine/chemistry , Peptides, Cyclic/chemistry , Technetium/chemistry , Tomography, Emission-Computed, Single-Photon/methods , Animals , Cell Line, Tumor , Chelating Agents/metabolism , Chelating Agents/pharmacokinetics , Humans , Integrin alphaVbeta3/analysis , Integrin alphaVbeta3/metabolism , Male , Mice, Inbred BALB C , Mice, Nude , Neoplasms/metabolism , Organotechnetium Compounds/metabolism , Organotechnetium Compounds/pharmacokinetics , Penicillamine/metabolism , Penicillamine/pharmacokinetics , Peptides, Cyclic/metabolism , Peptides, Cyclic/pharmacokinetics , Technetium/metabolism , Technetium/pharmacokinetics , Tissue DistributionABSTRACT
Pharmacokinetic studies concerning d-penicillamine (an acetaldehyde sequestering agent) are scarce and have not evaluated the influence of chronic ethanol consumption and age on its disposition. Since recent preclinical studies propose d-penicillamine as a promising treatment for alcohol relapse, the main aim of the present work was to evaluate the influence of these two factors on d-penicillamine disposition in order to guide future clinical studies on the anti-relapse efficacy of this drug in alcoholism. Additionally, the effect of the administered dose was also evaluated. To this end, three studies were carried out. Study 1 assessed the influence of dose on d-penicillamine disposition, whereas studies 2 and 3 evaluated, respectively, the influence of chronic alcohol consumption and age. Rapid intravenous administrations of 2, 10 and 30 mg/kg of d-penicillamine were performed using young or adult ethanol-naïve rats or adult ethanol-experienced (subjected to a long-term ethanol self-administration protocol) rats. Pharmacokinetic parameters were derived from the biexponential model. Statistical analysis of CL, normalized AUC0 (∞) , V1 and k10 revealed that disposition, in the range plasma concentrations assayed, is non-linear both in young ethanol-naïve and in adult ethanol-experienced rats. Notably, no significant changes in t1/2 were detected. Chronic ethanol consumption significantly reduced CL values by 35% without affecting t1/2 . d-Penicillamine disposition was equivalent in young and adult animals. In conclusion, although DP pharmacokinetics is non-linear, the lack of significant alterations of the t1/2 would potentially simplify the clinical use of this drug. Chronic consumption of ethanol also alters d-penicillamine disposition but, again, does not modify t1/2.
Subject(s)
Alcoholism/physiopathology , Chelating Agents/pharmacokinetics , Ethanol/administration & dosage , Penicillamine/pharmacokinetics , Age Factors , Animals , Area Under Curve , Chelating Agents/administration & dosage , Disease Models, Animal , Dose-Response Relationship, Drug , Half-Life , Male , Nonlinear Dynamics , Penicillamine/administration & dosage , Rats , Rats, WistarABSTRACT
BACKGROUND: D-Penicillamine is the most commonly used copper-chelating agent in the treatment of copper-associated hepatitis in dogs. Response to therapy can be variable, and there is a lack of pharmacokinetic information available for dogs. Coadministering the drug with food to alleviate vomiting has been recommended for dogs, which contradicts recommendations for drug administration to humans. HYPOTHESIS: Coadministration of d-penicillamine with food decreases relative bioavailability and maximum plasma drug concentrations (C(max)) in dogs. ANIMALS: Nine purpose-bred dogs with a median body weight of 17.0 kg. METHODS: Dogs received D-penicillamine (12.5 mg/kg PO) fasted and with food in a randomized, crossover design. Blood samples were collected before and 0.25, 0.5, 1, 2, 3, 4, 8, 12, and 24 hours after dosing. Total d-penicillamine concentrations were measured using liquid chromatography coupled with tandem quadrupole mass spectrometry. Pharmacokinetic parameters were calculated for each dog. RESULTS: Two fasted dogs (22%) vomited after receiving d-penicillamine. Mean C(max) ± standard deviation (SD) was 8.7 ± 3.1 µg/mL (fasted) and 1.9 ± 1.6 µg/mL (fed). Mean area under the plasma concentration curve ± SD was 16.9 ± 5.9 µg/mL·h (fasted) and 4.9 ± 3.4 µg/mL·h (fed). There were significant reductions in relative bioavailability and C(max) in fed dogs (P < .001). CONCLUSIONS AND CLINICAL IMPORTANCE: Coadministration of d-penicillamine with food significantly decreases plasma drug concentrations in dogs. Decreased drug exposure could result in decreased copper chelation efficacy, prolonged therapy, additional cost, and greater disease morbidity. Administration of d-penicillamine with food cannot be categorically recommended without additional studies.
Subject(s)
Chelating Agents/pharmacokinetics , Dogs/blood , Food Deprivation/physiology , Penicillamine/pharmacokinetics , Animals , Area Under Curve , Female , Half-Life , Male , Penicillamine/bloodABSTRACT
RATIONALE: Nowadays, very few approved anti-relapse treatments for alcoholism exist, and their overall efficacy can be considered moderate. An exciting rationale drug development opportunity for the treatment of chronic alcoholism is the use of acetaldehyde sequestering agents. Although these compounds are able to attenuate or prevent most of the behavioral and neurochemical effects of ethanol, the efficacy of acetaldehyde sequestration, by using agents such as D-penicillamine (DP), in relapse prevention has not been studied yet. OBJECTIVES: The aim of this study was to analyze the effects of DP treatment on the alcohol deprivation effect (ADE) in long-term ethanol-experienced rats as a model of relapse behavior and measure drug plasma and brain levels during treatment. METHODS: Rats were subcutaneously implanted with mini-osmotic pumps delivering 0, 0.25, or 1 mg/h of DP during 1 week. The efficacy to prevent ADE was determined. DP plasma and brain levels achieved during its subcutaneous administration were measured. In a second experiment, animals received bilateral infusions of 0 or 1.5 µg/h of DP directly into pVTA, and the appearance of ADE was evaluated. RESULTS: One milligram per hour, but not 0.25 mg/h, DP infusion prevented ADE and reduced the total ethanol preference in animals. DP plasma concentrations associated with ADE suppression were around 3-4 µg/ml, and brain DP levels in these conditions were about 2-3 % of those found in plasma. Intra-pVTA DP administration also suppressed ADE. CONCLUSION: DP is able to prevent alcohol-relapse-like drinking in rats suggesting that this drug may be a useful new tool in the management of relapse in alcohol-dependent patients.
Subject(s)
Alcohol Drinking/prevention & control , Alcoholism/drug therapy , Ethanol/administration & dosage , Penicillamine/pharmacology , Acetaldehyde/metabolism , Animals , Brain/metabolism , Chelating Agents/administration & dosage , Chelating Agents/pharmacokinetics , Chelating Agents/pharmacology , Dose-Response Relationship, Drug , Infusion Pumps, Implantable , Male , Osmotic Pressure , Penicillamine/administration & dosage , Penicillamine/pharmacokinetics , Rats , Rats, Wistar , Secondary Prevention , Time Factors , Tissue Distribution , Ventral Tegmental AreaABSTRACT
The synthesis, characterization and biological evaluation of two new neutral tricarbonyl fac-M(CO)(3)(SNO) (M=Re, (99m)Tc) bearing o-methoxyphenylpiperazine as pharmacophore and S-functionalized cysteine or penicillamine as chelators are reported. Competition binding tests showed good affinity for the 5-HT(1A) receptor (8 and 54 nM for 4a and 4b, respectively). Biodistribution studies in healthy animals showed high initial blood and liver uptake, fast blood and tissue depuration and negligible brain uptake.
Subject(s)
Cysteine/chemistry , Cysteine/pharmacokinetics , Penicillamine/chemistry , Penicillamine/pharmacokinetics , Receptor, Serotonin, 5-HT1A/metabolism , Technetium/chemistry , Technetium/pharmacokinetics , Animals , Isotope Labeling , Male , Metabolic Clearance Rate , Organ Specificity , Propiophenones/chemistry , Propiophenones/pharmacokinetics , Radiopharmaceuticals/chemistry , Radiopharmaceuticals/pharmacokinetics , Rats , Rats, Wistar , Tissue DistributionABSTRACT
We investigated anticancer therapy with a novel combination of D-penicillamine (D-pen) and Idarubicin (Ida) in a synthetic dual drug conjugate (DDC). D-pen and Ida were covalently linked to poly(α)-L-glutamic acid (PGA) via reducible disulfide and acid-sensitive hydrazone bonds, respectively. The DDCs showed cell uptake and sustained release of the bound drugs in conditions mimicking the intracellular release media (10mM glutathione and pH 5.2). The in-vitro cytotoxicity of DDCs was comparable to unconjugated Ida in several sensitive and resistant cancer cell lines and correlated with the rate of cell uptake. In a single equivalent-dose pharmacokinetic study, DDCs enhanced the drug exposure by 7-fold and prolonged the plasma circulation half-life (t(1/2)) by 5-fold over unconjugated Ida. The therapeutic index of DDCs was 2-3-fold higher than unconjugated drugs. DDCs caused 89% tumor growth inhibition compared to 60% by unconjugated Ida alone and led to significant enhancement in the median survival (17%) of athymic nu/nu mice bearing NCI-H460 tumor xenografts.
Subject(s)
Antineoplastic Agents/administration & dosage , Carcinoma, Non-Small-Cell Lung/drug therapy , Idarubicin/administration & dosage , Penicillamine/administration & dosage , Animals , Antineoplastic Agents/chemistry , Antineoplastic Agents/pharmacokinetics , Antineoplastic Combined Chemotherapy Protocols , Carcinoma, Non-Small-Cell Lung/pathology , Cell Line, Tumor , Humans , Idarubicin/chemistry , Idarubicin/pharmacokinetics , Male , Mice , Mice, Inbred BALB C , Mice, Nude , Penicillamine/chemistry , Penicillamine/pharmacokinetics , Peptides , Polyglutamic Acid/chemistry , Tissue Distribution , Tumor Burden/drug effects , Xenograft Model Antitumor AssaysABSTRACT
The current study was aimed at synthesizing a glucuronide derivative of D-penicillamine (D-PA) to be used for imaging purposes. First of all, D-PA-glucuronide (D-PA-Glu) was synthesized by experimental treatments starting with uridine 5'-diphospho-glucuronosyltransferase enzyme rich microsome preparate. Then, the synthesized compound was labeled with technetium ((99m)Tc) by using a reduction method with stannous chloride. Quality controls were performed by using high-performance liquid chromatography and thin-layer radio chromatography (TLRC). Radiolabeling yield of (99m)Tc-D-PA-Glu was more than 98% according to TLRC results. In vitro evaluations of radiolabeled complexes were investigated on PC-3 human prostate cancer cells. (99m)Tc-D-PA-Glu exhibited more accumulation on PC-3 cells versus (99m)Tc-D-PA at 240 minutes. In order to determine its radiopharmaceutical potential, biodistribution studies were carried out in male Albino Wistar rats. The biodistribution results of (99m)Tc-D-PA-Glu, showed the highest uptake in prostate at 120 minutes postinjection with the main excretion route being through kidneys and bladder. (99m)Tc-D-PA-Glu and (99m)Tc-D-PA have exhibited different biodistribution results.
Subject(s)
Glucuronides/chemical synthesis , Organotechnetium Compounds/chemical synthesis , Penicillamine/analogs & derivatives , Technetium/chemistry , Animals , Cell Line, Tumor , Chromatography, High Pressure Liquid , Glucuronides/chemistry , Glucuronides/pharmacokinetics , Humans , Male , Mass Spectrometry , Organotechnetium Compounds/chemistry , Organotechnetium Compounds/pharmacokinetics , Penicillamine/chemical synthesis , Penicillamine/chemistry , Penicillamine/pharmacokinetics , Prostatic Neoplasms/metabolism , Rats , Rats, Wistar , Tissue DistributionABSTRACT
El tratamiento de las enfermedades reumáticas estácondicionado por el hecho que, en su mayoría, sonprocesos de carácter crónico, y que salvo en contadasexcepciones, como por ejemplo las artritis infecciosas,no existen tratamientos curativos. Porello, el objetivo lógico de curar se debe de sustituirpor aliviar y conservar
Treatment of rheumatic diseases depends, in mostcases, on that they're chronic process and exceptsome exceptions, as for example infectious arthritis,palliatives treatments doesn't exist. Because of that,the cure logic objective must be replaced for releaseand conserve
Subject(s)
Humans , Rheumatic Diseases/drug therapy , Administration, Topical , Anti-Inflammatory Agents, Non-Steroidal/pharmacokinetics , Injections, Intra-Articular/methods , Adrenal Cortex Hormones/pharmacokinetics , Hypothalamo-Hypophyseal System , Chloroquine/pharmacokinetics , Penicillamine/pharmacokinetics , Antirheumatic Agents/pharmacokineticsABSTRACT
Metal ions accumulate in the brain with aging and in several neurodegenerative diseases. Aside from the copper storage disease, Wilson's disease, recent attention has focused on the accumulation of zinc, copper and iron in the Alzheimer's disease (AD) brain and the accumulation of iron in Parkinson's disease. In particular, the parenchymal deposition of beta-amyloid (Abeta) and its interaction with metal ions has been postulated to play a role in the progression of AD. Thus, the strategy of lowering brain metal ions and targeting the interaction of Abeta peptide and metal ions through the administration of chelators has merit. Our recent finding that nanoparticle delivery systems can cross the blood-brain barrier has led us to investigate whether chelators delivered conjugated to nanoparticles could act to reverse metal ion induced protein precipitation. In the present studies, the Cu (I) chelator D-penicillamine was covalently conjugated to nanoparticles via a disulfide bond or a thioether bond. Nanoparticle-chelator conjugates were stable between pH 6-8 in aqueous suspension if stored at 4 degrees C, and did not aggregate when challenged with salts and serum. Release of D-penicillamine from the nanoparticles was achieved using reducing agents such as dithiothreitol (as a model for glutathione). Nanoparticles treated only under reducing conditions that released the conjugated D-penicillamine were able to effectively resolubilize copper-Abeta (1-42) aggregates. These results indicate that nanoparticles have potential to deliver D-penicillamine to the brain for the prevention of Abeta (1-42) accumulation, as well as to reduce metal ion accumulation in other CNS diseases.
Subject(s)
Alzheimer Disease/drug therapy , Chelating Agents/administration & dosage , Chelating Agents/therapeutic use , Copper , Nanostructures , Penicillamine/administration & dosage , Alzheimer Disease/metabolism , Central Nervous System Diseases/drug therapy , Central Nervous System Diseases/metabolism , Chelating Agents/pharmacokinetics , Copper/metabolism , Drug Carriers/administration & dosage , Drug Carriers/pharmacokinetics , Drug Stability , Particle Size , Penicillamine/pharmacokineticsSubject(s)
Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/drug therapy , Arthritis, Rheumatoid/nursing , Antirheumatic Agents/economics , Antirheumatic Agents/pharmacokinetics , Arthritis, Rheumatoid/diagnosis , Drug Costs , Drug Monitoring/methods , Drug Monitoring/nursing , Gold Sodium Thiomalate/economics , Gold Sodium Thiomalate/pharmacokinetics , Gold Sodium Thiomalate/therapeutic use , Humans , Hydroxychloroquine/economics , Hydroxychloroquine/pharmacokinetics , Hydroxychloroquine/therapeutic use , Methotrexate/economics , Methotrexate/pharmacokinetics , Methotrexate/therapeutic use , Nurse's Role , Nursing Assessment , Penicillamine/economics , Penicillamine/pharmacokinetics , Penicillamine/therapeutic use , Sulfasalazine/economics , Sulfasalazine/pharmacokinetics , Sulfasalazine/therapeutic useABSTRACT
No disponible
Subject(s)
Catalysis , Nobel Prize , Chemistry, Pharmaceutical/methods , Chemistry, Pharmaceutical/organization & administration , Stereoisomerism , Thalidomide/pharmacology , Thalidomide/pharmacokinetics , Penicillamine/pharmacokinetics , Penicillamine/pharmacology , Ectromelia/drug therapy , Teratogens/pharmacology , Macromolecular SubstancesABSTRACT
Nitric oxide (NO) is one of the most versatile mediators in mammalian biology. In the present study, we investigated the absorption-enhancing effects of an NO donor, 3-(2-hydroxy-1-methylethyl-2-nitrosohydrazino)-N-methyl-1-propa namine (NOC7), on drugs that are poorly absorbed from the gastrointestinal tract. NOC7 significantly increased the jejunal absorption of fluorescein isothiocyanate dextrans (FDs) of different average molecular weights (4000-20,000). This enhancing effect decreased as the FD molecular weight increased. Another NO donor, S-nitroso-N-acetyl-DL-penicillamine (SNAP), also increased the absorption of FD-4 from the jejunum. The absorption enhancement effect of NOC7 significantly decreased after coadministration with an NO scavenger, 2-(4-carboxyphenyl)-4,4,5, 5-tetramethylimidazole-1-oxyl-3-oxide, sodium salt. Furthermore, the enhancement effect of NOC7 was reversed shortly after cessation of the enhancer treatment. Little damage by NOC7 to the intestinal mucosa was observed in terms of release of lactose dehydrogenase and protein from the intestinal mucosa. NOC7 also increased the absorption of FD-4 by the colon and rectum. The findings suggest that an NO donor can improve the absorption of macromolecules from all regions of the rat intestine with very little mucosal damage and that an NO donor can act as a potent absorption enhancer.
Subject(s)
Dextrans/pharmacokinetics , Fluorescein-5-isothiocyanate/analogs & derivatives , Intestinal Absorption/drug effects , Intestinal Mucosa/metabolism , Jejunum/metabolism , Nitric Oxide Donors/pharmacokinetics , Penicillamine/analogs & derivatives , Triazenes/pharmacology , Animals , Colon/metabolism , Dextrans/chemistry , Fluorescein-5-isothiocyanate/chemistry , Fluorescein-5-isothiocyanate/pharmacokinetics , Intestinal Absorption/physiology , Intestinal Mucosa/drug effects , Jejunum/drug effects , Macromolecular Substances , Male , Penicillamine/pharmacokinetics , Rats , Rectum/metabolismABSTRACT
The objective of this study was to evaluate the effect of a nitric oxide (NO) donor, S-nitroso-N-acetyl-DL-penicillamine (SNAP), on the nasal absorption of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in rabbits and to evaluate the irritation (cytotoxicity) potential of the NO donor on the mucosal membrane using a cultured cell system (strain KB, human epidermoid carcinoma of the floor of the mouth). Significantly higher serum G-CSF concentration and increased total leukocyte count in the peripheral blood were observed after coadministration of rhG-CSF (100 microg/kg) with SNAP at various doses (0.3-3.3 mg/kg). The serum G-CSF concentration and the increased total leukocyte count were markedly decreased by the presence of the NO scavenger, 2-(4-carboxyphenyl)-4,4,5,5-tetramethyl-imidazole-1-oxyl 3-oxide sodium salt (carboxy-PTIO), in combination with rhG-CSF and SNAP. However, no significant inhibitory effect of glutathione (peroxynitrite scavenger) on the absorption-enhancing effect of SNAP was observed. These results suggest that carboxy-PTIO inhibits the absorption-enhancing effect of NO released from SNAP. We found that SNAP has a very low potential for cytotoxicity, as evaluated by the cell detachment assay, release of lactate dehydrogenase (LDH) from cultured cells and morphological observations of nasal tissue of rabbits. It is concluded that a NO donor such as SNAP is a promising absorption enhancer for nasal protein-drug delivery.
Subject(s)
Administration, Intranasal , Granulocyte Colony-Stimulating Factor/pharmacokinetics , Nasal Mucosa/metabolism , Nitric Oxide Donors/pharmacokinetics , Penicillamine/analogs & derivatives , Animals , Cells, Cultured , Granulocyte Colony-Stimulating Factor/blood , Humans , Leukocyte Count , Male , Nasal Mucosa/drug effects , Nitric Oxide Donors/administration & dosage , Penicillamine/administration & dosage , Penicillamine/pharmacokinetics , Rabbits , Recombinant ProteinsABSTRACT
S-nitroso-N-acetyl penicillamine (SNAP, 0.1-0.5 mM) caused release of nitric oxide (NO) into the perfusion medium of immobilized hepatocytes. Oxidative injury of hepatocytes was evoked by tert-butyl hydroperoxide (TBH, 1 mM) and the functional and morphological ultrastructural integrity of the cells was monitored. At the end of a 270-min perfusion period, SNAP-induced NO reduced lactate dehydrogenase leakage in TBH-injured hepatocytes as compared to untreated TBH-injured cells (122% +/- 5 vs. 146% +/- 6 of control levels), lipid peroxides production (2.7 +/- 0.2 vs. 3.7 +/- 0.3 nmol/10(6) cells), increased O2 consumption (26 +/- 2 vs. 12 +/- 1 nmol/10(6) cells) although urea synthesis was reduced. SNAP improved the formation of granules in the Golgi complex as compared to untreated TBH-injured hepatocytes and preserved the ultrastructural architecture of mitochondria and the smooth endoplasmic reticulum. The present data support a possible protective role of NO in oxidative liver injury.
Subject(s)
Liver Diseases/drug therapy , Liver/drug effects , Nitric Oxide Donors/pharmacology , Nitric Oxide/physiology , Oxidative Stress/drug effects , Penicillamine/analogs & derivatives , Animals , Cells, Immobilized , Chemical and Drug Induced Liver Injury , Galactosamine/toxicity , Liver/cytology , Liver/metabolism , Liver Diseases/metabolism , Male , Nitric Oxide/pharmacokinetics , Penicillamine/pharmacokinetics , Penicillamine/pharmacology , Perfusion , Rats , Rats, Wistar , tert-Butylhydroperoxide/toxicityABSTRACT
Previous studies have shown a role for nitric oxide (NO) as a cytotoxic effector. In the present work, two chemically different NO-donors such as glyceryl trinitrate (GTN) and S-nitroso-N-acetylpenicillamine (SNAP) were evaluated for both NO release and cytostatic/cytotoxic properties. Nitrite accumulation in the supernatant of MCF-7 and U251 cell lines indicated a greater and quickly release of NO derived from SNAP. A time-course of hemoglobin absorption spectral changes showed a greater release of NO derived from GTN in presence of cells compared to the values observed in the media, confirming that the release of NO by GTN can be enzymatic and non-enzymatic. On the contrary, SNAP generated NO without contribution of cellular components and saturated oxyhemoglobin quickly, within 2 hours. Both NO-donors inhibited thymidine incorporation in a similar manner and dose-dependently in U251 cells, but not in MCF-7 cells, where SNAP at the highest tested dose of 1000 microM induced only a 33% cytostatic effect. About trypan blue exclusion test, after 24 h GTN and SNAP, releasing similar amounts of NO, showed comparable cytotoxic effects on U251 cells (50% dead cells), but not on MCF-7 cells, where GTN resulted more cytotoxic. From our data, the "in vitro" antitumoral activity of NO-donors seems to be related to the type of tumor cell lines, to the amount and duration of NO release.
Subject(s)
Cell Survival/drug effects , Enzyme Inhibitors/toxicity , Nitric Oxide Donors/toxicity , Nitric Oxide/metabolism , Nitroglycerin/toxicity , Penicillamine/analogs & derivatives , Biotransformation , Brain Neoplasms/pathology , Breast Neoplasms/pathology , Enzyme Inhibitors/pharmacokinetics , Female , Glioblastoma/pathology , Humans , Kinetics , Nitric Oxide Donors/pharmacokinetics , Nitroglycerin/pharmacokinetics , Penicillamine/pharmacokinetics , Penicillamine/toxicity , S-Nitroso-N-Acetylpenicillamine , Tumor Cells, CulturedABSTRACT
Wilson's disease is an autosomal recessive disorder of copper metabolism. Since the introduction of penicillamine treatment successful pregnancies have been reported. However little is known about the risks of breast feeding in patients on this medication. We describe the case of a patient suffering from Wilson's disease, who had two uncomplicated pregnancies and breast fed both children for a period of three months each. In the 22 year old gravida I para I the diagnosis of Wilson's disease had been previously made by liver biopsy and penicillamine therapy had been begun. At the time of her first presentation at our department she was 8 week pregnant. Her renal and liver function were normal. Neurologic or psychiatric symptoms were not observed. At 18 weeks the dosage of penicillamine was reduced from 900 mg/d to 750 mg/d. The course of the pregnancy remained uneventful. At 38 + 1 weeks a healthy boy of 3100 gm was delivered. 19 months later the patient presented again in the 16th week of her second pregnancy. Concerning Wilson's disease no major changes were observed, especially liver and renal function were not impaired. The dosage of penicillamin was reduced from 900 mg/d to 750 mg/d during the 21st week. The pregnancy again was uncomplicated and at 38 + 2 weeks resulted in the spontaneous deliver of a healthy boy, weighting 3940 gm. Both children were breast fed over a period of three months and with the exception of an icterus prolongatus no adverse effects were noted.
Subject(s)
Hepatolenticular Degeneration/diagnosis , Pregnancy Complications/diagnosis , Adult , Breast Feeding , Dose-Response Relationship, Drug , Female , Genetic Counseling , Hepatolenticular Degeneration/drug therapy , Hepatolenticular Degeneration/genetics , Humans , Infant, Newborn , Kidney Function Tests , Liver Function Tests , Male , Penicillamine/administration & dosage , Penicillamine/adverse effects , Penicillamine/pharmacokinetics , Pregnancy , Pregnancy Complications/drug therapyABSTRACT
Complex forming conditions of Penicillamine di sulfide with 99mTc have been specified. Labeling of penicillamine di sulfide with 99mTc by direct reduction with SnCl2 did not give favorable good results while the 99mTc complex of penicillamine can be easily obtained. Ligand exchange reaction with 99mTc-gluconate was attempted and a 95% labeling efficiency was obtained. Radiopharmaceutical potential of 99mTc-PADS (99mTc-Penicillamine di sulfide) has been investigated with a gamma camera in rabbits and the complex was found to be uptaken mostly by the liver and kidneys.
Subject(s)
Organotechnetium Compounds/chemical synthesis , Penicillamine/analogs & derivatives , Penicillamine/chemical synthesis , Radiopharmaceuticals/chemical synthesis , Animals , Gluconates/chemistry , Isotope Labeling/methods , Ligands , Organotechnetium Compounds/chemistry , Organotechnetium Compounds/pharmacokinetics , Penicillamine/chemistry , Penicillamine/pharmacokinetics , Rabbits , Radiopharmaceuticals/pharmacokinetics , Tissue DistributionABSTRACT
The propensity of a cell to undergo apoptosis has been proposed to be a determinant of sensitivity to anti-microtubule agents. The anti-microtubule agents vincristine and paclitaxel induce key features of apoptosis, such as intranucleosomal DNA fragmentation and changes in nuclear morphology in the human neuroblastoma cell line, NB-39-nu. Nitric oxide (NO) generated from NO-releasing drugs prevented anti-microtubule agent-induced apoptosis in this cell line. The mechanism of suppression of apoptosis by NO appears to be via the inhibition of an interleukin-1beta converting enzyme-like protease cascade. This finding reveals a new biological function of NO, as well as a new molecular insight into resistance to chemotherapy with anti-microtubule agents.